Tag Archives: Tacrine

Pharmacological Treatment of Dementia

General guidelines for psychotropic medication use in frail elderly patients are applicable. Systematic evidence to support the effectiveness of particular psychotropic drugs in dementia patients is limited. Therefore, choice of drug class may be based on clinical evidence, and choice of agent is often based on the side-effect profile and on the characteristics of a… Read More »

Alzheimer’s Therapy: Acetylcholinesterase Inhibitors

Overview. Acetylcholinesterase inhibitors are the only drugs approved for the treatment of mild to moderate Alzheimer’s disease in the major markets. acetylcholinesterase inhibitors do not cure Alzheimer’s disease but do alleviate the cholinergic deficit observed in Alzheimer’s disease patients. Cognitive symptoms are occasionally improved but most often are only stabilized by the drugs (). Studies… Read More »

Information about Alzheimer’s Disease for Patients and Families

Alzheimer’s disease is the most common and well-known form of degenerative dementia. By definition, dementia is a syndrome, a cluster of symptoms, of impaired memory and cognition. Dementia is a cognitive disorder that impairs an individual’s memory and ability for reasoning, awareness, and judgment. Cognitive impairment in Alzheimer’s disease may involve disturbance of language (aphasia),… Read More »

Delirium: Neuropathogenesis

Even though delirium has many different etiologies, its constellation of symptoms is largely stereotyped, with some considered core symptoms. Somehow, this diversity of physiological perturbations translates into a common clinical expression that may represent dysfunction ofcertain neural circuits (as well as neurotransmitters) —  that is, a final common neural pathway. The involvement of certain specific… Read More »

Delirium: Pharmacological Treatment

Current delirium pharmacotherapies have evolved from use in the treatment of mainstream psychiatric disorders; hence, psychiatrists are well acquainted with the practicalities of their use. Medications are implicated as significant contributing factors in more than one-third of cases and can act as either protective or risk factors for delirium, depending on the drug. Pharmacological treatment… Read More »

Disease-Specific Treatments

The cholinergic hypothesis Although ideally one would wish for a cure based on correcting the underlying pathology of dementia, we must realistically treat symptoms and hope for the success of stabilization and preventive approaches for conditions such as Alzheimer’s disease and vascular dementia. Symptomatic treatment of Alzheimer’s disease is currently based on the cholinergic hypothesis,… Read More »

The cholinesterase inhibitors in Alzheimer’s disease

The history of cholinergic pharmacotherapy for Alzheimer’s disease was recently reviewed () and is characterized by the failure of acetylcholine precursors, releasing agents, and selective muscarinic agonists, but positive results with cholinesterase inhibitors. These drugs have been studied individually and the value of combination therapy, looking for pharmacological synergism as in dopamine enhancement for Parkinson’s… Read More »

Practical issues in using cholinesterase inhibitors

This review of published work combined with clinical experience brings out certain common characteristics among cholinesterase inhibitors: • Gastrointestinal side-effects (nausea, vomiting, diarrhoea, anorexia) are dose-related and transient, avoidable to a great extent by a slower titration up to therapeutic doses (Table Therapeutic closes of cholinesterase inhibitors in clinical use); they may be a limiting… Read More »

Anti-Alzheimer’s Drugs

Pharmacologic Profile General Use Management of Alzheimer’s dementia. General Action and Information All agents act by increasing the amount of acetylcholine in the CNS by inhibiting cholinesterase. No agents to date can slow the progression of Alzheimer’s dementia. Current agents may temporarily improve cognitive function and therefore improve quality of life. Contraindications Hypersensitivity. Tacrine should… Read More »

Matching SSRI to Depressive Subtype

Atypical Depression Atypical depression is characterized by mood reactivity and two of the following: weight or appetite increase, hypersomnia, leaden paralysis and a pattern of interpersonal rejection sensitivity. MAOIs have been found to be superior to TCAs for atypical depression but recent views are that SSRIs are also an effective treatment for this subtype. Response… Read More »